Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- Check6 days agoChange DetectedAdded a new revision tag 'Revision: v3.5.2' and removed the older tag 'Revision: v3.5.0'.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a new publication to the Publications section: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024 Nov;25(11):1465-1475.SummaryDifference0.1%

- Check35 days agoChange DetectedHepatocellular carcinoma has been added as the condition and the Genetic and Rare Diseases Information Center has been added to the resources. The page revision has been updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.2%

- Check42 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded a new revision tag (Revision: v3.4.2). Removed an operational status notice about government funding, while the study details and status remain unchanged.SummaryDifference0.4%

- Check78 days agoChange DetectedA new notice warns that information on the site may not be up to date due to a lapse in government funding, with a link to opm.gov for status updates. The page version has been updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.